Trials / Not Yet Recruiting
Not Yet RecruitingNCT07109375
Observational Study on Long-term Use of Pegunigalsidase Alfa in Fabry Patients in a Real-world Setting
Observational Prospective Cohort Study on Long-term Effective and Safe Use of Pegunigalsidase Alfa in Adult Fabry Patients Under "Real-world" Setting
- Status
- Not Yet Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 75 (estimated)
- Sponsor
- Chiesi Italia · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
PEGASO is an observational study designed to collect prospective data on the effectiveness and safety of pegunigalsidase alfa in adult patients with Fabry disease, being treated or planning to start treatment, under real-world setting.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | pegunigalsidase alfa | Pegunigalsidase alfa is 2 mg/mL concentrate for solution and is administered via intravenous infusion every two weeks. |
Timeline
- Start date
- 2026-04-01
- Primary completion
- 2028-12-01
- Completion
- 2028-12-01
- First posted
- 2025-08-07
- Last updated
- 2026-02-24
Locations
1 site across 1 country: Italy
Source: ClinicalTrials.gov record NCT07109375. Inclusion in this directory is not an endorsement.